SABS – sab biotherapeutics, inc. (US:NASDAQ)
Stock Stats
News
SAB Biotherapeutics, Inc. (NASDAQ: SABS) had its price target lowered by analysts at Chardan Capital from $25.00 to $20.00. They now have a "buy" rating on the stock.
SAB Biotherapeutics, Inc. (NASDAQ: SABS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
SAB BIO Reports Full Year 2024 Operating and Financial Results
SAB BIO to Participate in Upcoming Investor Conferences [Yahoo! Finance]
SAB BIO to Participate in Upcoming Investor Conferences
Form S-8 SAB Biotherapeutics,
Form 4 SAB Biotherapeutics, For: Mar 27 Filed by: Kropotova Alexandra
Form 10-K SAB Biotherapeutics, For: Dec 31
Form SCHEDULE 13G/A SAB Biotherapeutics, Filed by: RTW INVESTMENTS, LP
Form 8-K SAB Biotherapeutics, For: Jan 30
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.